Current Anti-VEGF Biosimilars Approved for Ophthalmologic Conditions

Rishi P. Singh, MD; and Michael A. Klufas, MD, provide an overview of the 2 currently available ophthalmology biosimilars, ranibizumab-eqrn and ranibizumab-nuna, as well as discuss which patient populations will benefit from these treatments.

Related Keywords

Michaela Klufas , ,Biosimilars ,Ophthalmology ,Wet Amd ,Age Related Macular Edema ,Ranibizumab Nuna ,Ranibizumab Eqrn ,